vTv Therapeutics Inc. Investing cash flow

Investing cash flow of VTVT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Investing cash flow growth rates and interactive chart.


Highlights and Quick Summary

  • Investing cash flow for the quarter ending December 30, 2019 was $-68 Thousand (a -121.94% decrease compared to previous quarter)
  • Year-over-year quarterly Investing cash flow increased by 1260.0%
  • Annual Investing cash flow for 2019 was $242 Thousand (a 3357.14% increase from previous year)
  • Annual Investing cash flow for 2018 was $7 Thousand (a -128.0% decrease from previous year)
  • Annual Investing cash flow for 2017 was $-25 Thousand (a -69.88% decrease from previous year)
  • Twelve month Investing cash flow ending December 30, 2019 was $237 Thousand (a -22.3% decrease compared to previous quarter)
  • Twelve month trailing Investing cash flow decreased by -2254.55% year-over-year
Trailing Investing cash flow for the last four month:
30 Dec '19 29 Sep '19 30 Dec '18 29 Sep '18
$237 Thousand $305 Thousand $7 Thousand $-11 Thousand
Visit stockrow.com/VTVT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Investing cash flow of vTv Therapeutics Inc.

Most recent Investing cash flowof VTVT including historical data for past 10 years.

Interactive Chart of Investing cash flow of vTv Therapeutics Inc.

vTv Therapeutics Inc. Investing cash flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $-0.07 $0.31 $0.24
2018 $0.0 $-0.01 $0.0 $0.01 $0.01
2017 $-0.02 $0.03 $0.0 $-0.04 $-0.03
2016 $0.0 $0.0 $-0.08 $0.0 $-0.08
2015 $-0.04 $-0.01 $-0.03 $-0.0 $-0.08
2014 $0.2 $-0.01 $-0.03 $0.16
2013 $-0.15 $-0.16

Business Profile of vTv Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.